Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma

Wu, Yuan‐Hung; Hung, Yi‐Ping; Chiu, Nai‐Chi; Lee, Rheun‐Chuan; Li, Chung–Pin; Chao, Yee; Shyr, Yi‐Ming; Wang, Shin‐E; Chen, Shih‐Chin; Lin, Sheng‐Hsuan; Chen, Yi‐Hsuan; Kang, Yu‐Mei; Hsu, Shih‐Min; Yen, Sang‐Hue; Wu, Jeng You; Lee, Kuan-Der; Tseng, Huey-En; Tsai, Jia-Ruey; Tang, Jui-Hsiang; Chiou, Jeng‐Fong; Burnouf, Thierry; Chen, Yin‐Ju; Wang, Peng‐Yuan; Lu, Long‐Sheng

doi:10.1016/j.ejca.2022.01.030

Cited by 21 publications

(23 citation statements)

References 32 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first reported CTC-derived organoid from an mPrCa patient reproduced the molecular heterogeneity of the primary tumor and was used for further mutational analysis . Recently, studies of three more CTC-derived organoids were reported from pancreatic ductal adenocarcinoma (PDAC) , and CRC …”

Section: D Matrixes As Physiologically Relevant Hosts For Ctcs: Curre...mentioning

confidence: 99%

“…The first reported CTC-derived organoid from an mPrCa patient reproduced the molecular heterogeneity of the primary tumor and was used for further mutational analysis. 106 Recently, studies of three more CTC-derived organoids were reported from pancreatic ductal adenocarcinoma (PDAC) 107,108 and CRC. 109 Although 2D or wet-based 3D strategies can provide useful tumor models (Figure 3a, 3b), they often lack the architectural and compositional features of the tumor microenvironment (TME).…”

Section: Hosts For Ctcs: Current Trends and Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Tumor Cells in Cancer Diagnostics and Prognostics by Single-Molecule and Single-Cell Characterization

Chowdhury¹,

Cressiot

Parisi

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) represent an interesting source of biomarkers for diagnosis, prognosis, and the prediction of cancer recurrence, yet while they are extensively studied in oncobiology research, their diagnostic utility has not yet been demonstrated and validated. Their scarcity in human biological fluids impedes the identification of dangerous CTC subpopulations that may promote metastatic dissemination. In this Perspective, we discuss promising techniques that could be used for the identification of these metastatic cells. We first describe methods for isolating patient-derived CTCs and then the use of 3D biomimetic matrixes in their amplification and analysis, followed by methods for further CTC analyses at the single-cell and single-molecule levels. Finally, we discuss how the elucidation of mechanical and morphological properties using techniques such as atomic force microscopy and molecular biomarker identification using nanopore-based detection could be combined in the future to provide patients and their healthcare providers with a more accurate diagnosis.

show abstract

Section: D Matrixes As Physiologically Relevant Hosts For Ctcs: Curre...mentioning

confidence: 99%

Section: Hosts For Ctcs: Current Trends and Future Directionsmentioning

confidence: 99%

Circulating Tumor Cells in Cancer Diagnostics and Prognostics by Single-Molecule and Single-Cell Characterization

Chowdhury¹,

Cressiot

Parisi

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

show abstract

“…More reports were given by a team from Taipei who successfully achieved ex vivo expansion and drug sensitivity screening of CTCs from SCLC [ 69 ], head and neck cancer (HNC) [ 70 ], and PDAC [ 71 ] patients, utilizing a lab-developed CTC culture platform called eSelect. Instead of using an extracellular matrix, the eSelect platform applied a biomimetic substrate called binary colloidal crystal (BCC) monolayers to construct a complex topographic surface [ 72 ].…”

Section: Studying Ctcs and Ctc Clusters In Pdx And Pdomentioning

confidence: 99%

“…CTC-derived organoids have the advantages of a higher success rate, shorter generation time, and greater amenability to gene editing compared to CDX. Nevertheless, CTC-derived organoids have only been built in a few cancers, including PCa [ 16 ], lung cancer [ 68 ], head and neck cancer [ 70 ], and PDAC [ 71 ]. Additional efforts should be made to establish organoids derived from CTCs of other types of cancer, and to generate a biobank of CTC-derived organoids.…”

Section: Studying Ctcs and Ctc Clusters In Pdx And Pdomentioning

confidence: 99%

The functional and clinical roles of liquid biopsy in patient-derived models

Zhu

Shen

et al. 2023

J Hematol Oncol

View full text Add to dashboard Cite

The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) and extracellular vesicles (EVs) in the patient's body fluid. Liquid biopsy has important roles in translational research. But its clinical utility is still under investigation. Newly emerged patient-derived xenograft (PDX) and CTC-derived xenograft (CDX) faithfully recapitulate the genetic and morphological features of the donor patients’ tumor and patient-derived organoid (PDO) can mostly mimic tumor growth, tumor microenvironment and its response to drugs. In this review, we describe how the development of these patient-derived models has assisted the studies of CTCs and CTC clusters in terms of tumor biological behavior exploration, genomic analysis, and drug testing, with the help of the latest technology. We then summarize the studies of EVs and cfDNA/ctDNA in PDX and PDO models in early cancer diagnosis, tumor burden monitoring, drug test and response monitoring, and molecular profiling. The challenges faced and future perspectives of research related to liquid biopsy using patient-derived models are also discussed.

show abstract

“…In peripheral blood samples of patients who have developed metastases, liquid biopsies containing circulating tumor cells (CTCs) can be used to provide a real-time and minimally invasive source of tumor cells [ 16 , 17 ]. In recent years, the collection of CTCs has expanded to liquid biopsies of patients with head and neck cancers [ 16 ], breast cancer [ 18 ], non-small-cell lung cancer [ 19 ], and prostate cancer [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases

et al. 2023

View full text Add to dashboard Cite

Primary intracranial ependymoma is a challenging tumor to treat despite the availability of multidisciplinary therapeutic modalities, including surgical resection, radiotherapy, and adjuvant chemotherapy. After the completion of initial treatment, when resistant tumor cells recur, salvage therapy needs to be carried out with a more precise strategy. Circulating tumor cells (CTCs) have specifically been detected and validated for patients with primary or recurrent diffused glioma. The CTC drug screening platform can be used to perform a mini-invasive liquid biopsy for potential drug selection. The validation of potential drugs in a patient-derived xenograft (PDX) mouse model based on the same patient can serve as a preclinical testing platform. Here, we present the application of a drug testing model in a six-year-old girl with primary ependymoma on the posterior fossa, type A (EPN-PFA). She suffered from tumor recurrence with intracranial and spinal seeding at 2 years after her first operation and extraneural metastases in the pleura, lung, mediastinum, and distant femoral bone at 4 years after initial treatment. The CTC screening platform results showed that everolimus and entrectinib could be used to decrease CTC viability. The therapeutic efficacy of these two therapeutic agents has also been validated in a PDX mouse model from the same patient, and the results showed that these two therapeutic agents significantly decreased tumor growth. After precise drug screening and the combination of focal radiation on the femoral bone with everolimus chemotherapy, the whole-body bone scan showed significant shrinkage of the metastatic tumor on the right femoral bone. This novel approach can combine liquid biopsy, CTC drug testing platforms, and PDX model validation to achieve precision medicine in rare and challenging tumors with extraneural metastases.

show abstract

Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma

Cited by 21 publications

References 32 publications

Circulating Tumor Cells in Cancer Diagnostics and Prognostics by Single-Molecule and Single-Cell Characterization

Circulating Tumor Cells in Cancer Diagnostics and Prognostics by Single-Molecule and Single-Cell Characterization

The functional and clinical roles of liquid biopsy in patient-derived models

Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases

Contact Info

Product

Resources

About